Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Chemotherapy data

From: LDH and hemoglobin outperform systemic inflammatory indices as prognostic factors in patients with soft tissue sarcoma undergoing neoadjuvant treatment

Variable

Strata

n (%)

Total chemotherapy cycles

 

Median [range] 5 [1–8]

Chemotherapy protocol

AI

107 (87)

AD

16 (13)

Neoadjuvant chemotherapy

Yes

123 (100)

No

0 (0)

Neoadjuvant chemotherapy cycles

Median [range]

4 [1–8]

Dose reduction

Yes

26 (21)

No

97 (79)

Reason for dose reduction

Hematological toxicity

25 (96)

Other

1 (4)

  1. AI = Doxorubicin + Ifosfamide, AD = Doxorubicin + Dacarbazine
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us